Visual Format: Side-effect and safety matrix Key Labels: Topical irritation, allergic reaction, formulation sensitivity, wound-care context, injectable route, limited safety data, peptide impurities, immunogenicity risk Suggested Layout: Create a three-column matrix: Topical products, Wound-care study context, and Injectable or compounded preparations. Under each column, list route-specific safety considerations using short, neutral labels
They used folic acid cation (FA) and triphenylphosphonium (TPP) to create a dual-targeting pro-apoptotic peptide [69]
They had a body mass index (BMI) of at least 30 on the date of treatment initiation or during the latest available primary care visit, or a BMI of at least 27 with one or more weight-related comorbidities such as hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease
181 Further, the activity of G6PD is also repressed by aspirin casing acetylation of G6PD to decrease the activity of G6PD and the generation of NADPH, and by RRx-001, a novel clinical-stage chemosensitizer and radiosensitizer, which exerts antiproliferative effects in human tumor cells